Background: This double-blind, randomized controlled design study aimed to assess the dose-dependent effects of synbiotics on gastrointestinal symptoms of and fatigue in irritable bowel syndrome (IBS). Methods: Thirty subjects with IBS were randomly assigned into the following three groups and received 2 capsules a day for 8 weeks: (1) high-dose (2 capsules of synbiotics); (2) low-dose (1 capsule of synbiotics and 1 capsule of placebo); and (3) placebo (2 capsules of placebo). At baseline and 8 weeks, they completed the study questionnaires. Results: Two subjects in the high-dose group were lost to follow-up, leaving a total of 28 patients for the analysis. After 8 weeks, abdominal discomfort, abdominal bloating, frequency of formed stool, fatigue Visual Analog Scale (VAS), and Multidimensional Fatigue Inventory were significantly different among the groups (P=0.002, 0.006, 0.007, 0.028, and 0.041, respectively, by Kruskal-Wallis test). However, only abdominal discomfort, abdominal bloating, frequency of formed stool, and fatigue VAS were significantly improved in the high-dose group compared with those in the placebo group (P=0.002, 0.003, 0.002, and 0.013, respectively) by Mann-Whitney test with Bonferroni correction. No adverse drug reactions were reported. Conclusion: High-dose synbiotics were superior to placebo in improving bowel symptoms and fatigue of IBS patients, suggesting that synbiotic dosage plays an important role in the treatment of IBS.
INTRODUCTION

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) dis-
order characterized by abdominal pain, abdominal discomfort, and altered bowel habits.
1) The prevalence of IBS is reported as approximately 5%-10% of the general population with a female predominance in South Korea.
2) It has a negative impact on health-related quality of life and induces high health costs in Asian populations as well as Western countries. 3) Although the precise etiology of IBS is still unknown, emerging evidence suggests that gut flora play a pathological role. 4, 5) The corollary to this theory is the possible benefit of probiotics for IBS symptoms, and several meta-analyses have concluded that probiotics containing specific strains do improve the global symptoms of IBS and abdominal pain. 6, 7) Therefore, recent interest has focused on agents such as proand prebiotics whose actions are confined to the lumen, with a per- Thus, we investigated the dose-response effects of synbiotic supplementation on bowel symptoms and fatigue in IBS patients.
METHODS
Study Design and Subjects
This study was a single-center, randomized, double-blind, and placebo-controlled clinical trial. Among the subjects who visited the health promotion center of Ajou University Hospital from June 2015 to October 2015, those who met the Rome III criteria for IBS were enrolled in this study (Figure 1 ). IBS patients aged ≥19 years were recruited, and initial screening included medical history taking, physical examination, and laboratory testing. We excluded subjects who met one of the following conditions: subjects with organic GI disease such as inflammatory bowel disease and a history of gluten intolerance (celiac disease); subjects taking antibiotics, synbiotics (including probiotics only), or any other drug that could influence bowel function within 1 month of consumption; the subjects with previous abdominal surgery except for appendectomy; pregnant or breastfeeding females; subjects with evidence of other organic, metabolic, or psychiatric diseases that could impact compliance as well as those with poor medication compliance.
Of the 38 subjects who underwent the screening process, eight applicants were excluded according to the inclusion/exclusion criteria.
Therefore, 30 subjects were initially enrolled in the study; of these, 28 subjects completed this study, as two were withdrawn for unknown reasons.
All the subjects completed an informed consent form before partici- 
Study Protocol & Randomization
The subjects were randomly assigned at a 1:1:1 ratio to the high-dose, low-dose, or placebo groups according to block randomization. We did not control any variables during randomization. The patients, investigators, doctors, and study nurses were blinded using randomization codes, which were kept confidential until the end of data analysis.
The placebo group took 2 capsules of placebo, the low-dose group received 1 capsule of placebo and 1 capsule of synbiotics, and the highdose group received 2 capsules of synbiotics. The study drugs were administered once a day for 8 weeks. All patients filled in fatigue and bowel symptom questionnaires at the first and last visit. After 4 weeks of the study, all subjects were revisited and their physical condition, vital signs, study compliance, and adverse events were evaluated. Their laboratory test results, study compliance, and adverse events were then re-checked after the completion of 8 weeks of the study. During the entire study period, all patients were prohibited from consuming yogurt or taking pre-or probiotic pills or other GI drugs.
Sample Size Estimation
The size of the study sample was not based on a power calculation owing to the absence of reliable calculation data about synbiotics in IBS.
Instead, it was considered adequate to characterize a potential effect with sufficient accuracy based on previous experience gained through similar studies. [8] [9] [10] In other words, the previous two studies were performed with 25 subjects and 24 subjects with a double-blind randomized design, respectively. 8, 10) In another single-blind randomized controlled trial (RCT) of 30 patients that investigated the effects of probiotics on intestinal permeability in IBS, 9) the authors estimated that the sample size of 30 patients had a power of 80% to detect a difference of 30% in the proportion of increased small bowel permeability between the placebo and the probiotics group after treatment at the significance level of 5% with a low dropout rate (<5%).
Synbiotics & Placebo Preparation
The investigational drug was Ultra-Probiotics-500, supplied by B&A Health Products Inc., Los Angeles, CA, USA. Each capsule contains 10 billion colony-forming units of probiotic bacteria comprising six strains of Lactobacillus (rhamnosus, acidophilus, casei, bulgaricus, plantarum, and salivarius) and two strains of Bifidobacterium (bifidum and longum). Each capsule also contains 175 mg of fructooligosaccharides, 150 mg of Ulmus davidiana (Slippery elm bark powder), 10 mg of Geum urbanum (herb bennet) powder, and 100 mg of inulin powder as prebiotics. The placebo was encapsulated in the same material as the synbiotic capsule, and the content of the capsule was manufactured such that it could not be distinguished by taste or color.
Data Collection
1) Blood sampling
Blood samples were drawn after midnight fasting. We checked the complete blood cell count and tested liver function by examining the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltranspeptidase (GGT) and renal function by assessing the levels of blood urea nitrogen (BUN) and creatinine.
2) IBS Symptom Questionnaire
The primary endpoints included severity of the Visual Analog Scale 
3) Fatigue Questionnaire
To assess the degree of fatigue symptoms in IBS patients, we used the Fatigue Severity Scale (FSS).
12) The FSS contains nine items, each of which is ranked for degree of severity using a scale of 1 (none) to 7
(very severe); the score is the average of the nine items. We also used the fatigue VAS to assess the degree of global fatigue, using a scale of 0 (no fatigue) to 10 (very severe fatigue). Additionally, we used the 20- 
Statistical Analysis
The data were examined using intention-to-treat (ITT) and per-protocol (PP) analyses. For the ITT analysis, all data from the study subjects were included. For missing or incomplete data, the most recently available data were used for a last-observation-carried-forward (LOCF) analysis. For the PP analysis, only the data obtained from the subjects who completed the study on schedule were included, and the analysis was performed only when the data were available at weeks 0 and 8. Of the 30 subjects who enrolled in the study, two subjects were withdrawn (from the high-dose group) and none were omitted due to noncompliance. All side effects were reported and noted in detail, regardless of their relevance to the study drug.
Descriptive statistics and a frequency analysis were performed to describe the clinical characteristics of the study subjects. We used the There were no significant differences between the three groups with respect to gender, abdominal discomfort, abdominal bloating, frequency of formed stool, epigastric soreness, and nausea; only the age of the subjects showed differences (P=0.086, 0.286, 0.255, 0.384, 0.506, 0.399, and 0.020, respectively). The differences in age (and gender proportion, even it was not significant) at baseline were considered a random error due to the small numbers of subjects in each study group.
RESULTS
Baseline Characteristics
In addition, there were no significant differences between the groups in terms of baseline biochemistry characteristics, including white 
Changes in Variables after Intervention
Abdominal discomfort, abdominal bloating, fatigue VAS, and MFI in the low-dose and high-dose groups were significantly improved after (Table 3) 
Correlations between Study Groups and Variables after Intervention
Correlations between study groups and variables after intervention were determined by Spearman's rank correlation test ( 
Safety Assessment
In this clinical trial, there were no reports of any significant adverse events during the study or any subjects experiencing either serious adverse events or withdrawal due to adverse events.
DISCUSSION
The present randomized, double-blind, and placebo-controlled study IBS. Second, the anti-inflammatory capability of synbiotics should be considered. A previous in vitro study has elucidated that synbiotics decrease inflammation in IBS. 21) Moreover, chronic inflammation is considered an important contributing factor to bowel symptoms. For example, inflammatory cytokines are increased in IBS patients and may be associated with GI symptoms. 22) In ulcerative colitis, increased inflammation reflects disease activity and correlates with severity of symptoms. 23) Inflammatory cytokines inhibit normal bowel functions, including water re-absorption by colonic villi, and bowel dysfunction may trigger bowel symptoms. 24) Therefore, the anti-inflammatory effects of synbiotics may result in improved GI symptoms in IBS patients.
The present study showed significant improvement in fatigue VAS after an 8-week treatment period with high-dose synbiotics. Fatigue may be considered in relation to gut microorganisms because gut microbial disruption induces biochemical and genetic changes in the brain associated with psychiatric conditions including anxiety and depression. 25) Indeed, administration of probiotics significantly reduces the recovery time from fatigue after forced swimming in rats. 17) However, until now, there exist only few data on the effect of synbiotics on fatigue in human studies; therefore, the precise role of synbiotics in IBS-related mental problems should be investigated in the future.
In our data, only high-dose synbiotics were associated with significant improvement in IBS symptoms and fatigue compared with placebo. Previous studies on the optimal dose of synbiotics in IBS consist of four RCTs. 14, 15, 26, 27) Of these, three studies indicated positive results and one showed a negative result. This discrepancy may be due to variations in inclusion criteria for the subjects, sample size, study design, and synbiotic dosage. 28) Of these heterogeneous factors, our study suggests that dosage plays an important role in the therapeutic effects of IBS. This finding may also be supported by our data. Although no significant dose-dependent clinical effects of synbiotics were observed, a trend toward a dose-response relationship was observed.
Our study has some limitations. First, since the sample size of the current study was small, we used nonparametric analysis. In addition,
we were unable to perform subgroup analysis by IBS subtypes because of the small sample size. A large-scale prospective study should be performed to investigate the efficacy of synbiotics on bowel symptoms and fatigue in IBS subtypes. Second, the direct measurement of fecal microbial levels for the restoration of normal flora after synbiotic supplementation has not been performed. However, in previous studies, it has been shown that probiotics and prebiotics were able to modify the gut flora in healthy volunteers. 29, 30) Finally, an 8-week study period may be too short to confirm the long-term benefits and side effects of synbiotics.
Otherwise, our study is another well-designed RCT examining the efficacy and safety of synbiotics in IBS that used fatigue scales to assess the degree of fatigue symptoms in IBS. Moreover, our study has the strength of being the first to evaluate the dose-response relationship between synbiotics and gut symptoms and fatigue in IBS.
In summary, this study indicates that high-dose synbiotics containing Lactobacillus, Bifidobacterium, and fructooligosaccharides are effective and safe for the treatment of abdominal discomfort, abdominal bloating, formed stool frequency, and fatigue symptoms in IBS. In addition, although were no significant dose-dependent clinical effects of synbiotics were noted, a trend toward a dose-response relationship was demonstrated. In the future, further large-scale studies to determine the association between optimal dosage of synbiotics and IBS are warranted.
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